HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49%…
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this…